Skip to content

Study · Randomized controlled trial · 2015

5 results

Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study).

Xu W, Bi Y, Sun Z, Li J, Guo L, Yang T, Wu G, Shi L, Feng Z, Qiu L, Li Q, Guo X and 17 more

Show all authors

Luo Z, Lu J, Shan Z, Yang W, Ji Q, Yan L, Li H, Yu X, Li S, Zhou Z, Lv X, Liang Z, Lin S, Zeng L, Yan J, Ji L, Weng J

Journal of internal medicine5 Aug 2014Cited by 46 (Europe PMC)

PMID25039675 (opens in a new tab)DOI10.1111/joim.12293 (opens in a new tab)PepBankPUB-25039675
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In newly diagnosed type 2 diabetes patients, exenatide reduced HbA1c by 1.8% from baseline at week 48.

    In plain wordsIn patients with newly diagnosed diabetes, exenatide lowered HbA1c by 1.8% from baseline at week 48.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c change from baseline
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 48 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −1.8%
    exenatide

    Source sentences

    Summary
    At week 48, mean [95% confidence interval (CI)] HbA1c changes from baseline were -1.8% (-1.55% to -2.05%) with exenatide, -1.7% (-1.52% to -1.96%) with insulin and -1.5% (-1.23% to -1.71%) with pioglitazone.
    1 context sentence
    Summary · context
    In this 48-week, multicentre, parallel-group study, 416 patients newly diagnosed with type 2 diabetes were randomly assigned 1 : 1 : 1 to receive exenatide, insulin or pioglitazone.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In newly diagnosed type 2 diabetes patients, HbA1c change did not differ significantly between exenatide and insulin.

    In plain wordsIn patients with newly diagnosed diabetes, HbA1c change did not differ significantly between exenatide and insulin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeHbA1c versus insulin
    Study

    n: not reported in source

    Comparator
    Insulin
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 48 weeksAs given in this study (human).

    Measurements

    HbA1c treatment difference
    −0.2%
    exenatide versus insulin

    Source sentences

    Summary
    Treatment differences were -0.20% (95% CI -0.46% to 0.06%) for exenatide versus insulin (P = 0.185), and -0.37% (95% CI -0.63% to -0.12%) for exenatide versus pioglitazone (P = 0.002).
    1 context sentence
    Summary · context
    In this 48-week, multicentre, parallel-group study, 416 patients newly diagnosed with type 2 diabetes were randomly assigned 1 : 1 : 1 to receive exenatide, insulin or pioglitazone.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In newly diagnosed type 2 diabetes patients, exenatide reduced HbA1c more than pioglitazone.

    In plain wordsIn patients with newly diagnosed diabetes, exenatide lowered HbA1c more than pioglitazone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c versus pioglitazone
    Study

    n: not reported in source

    Comparator
    Pioglitazone
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 48 weeksAs given in this study (human).

    Measurements

    HbA1c treatment difference
    −0.37%
    exenatide versus pioglitazone

    Source sentences

    Summary
    Treatment differences were -0.20% (95% CI -0.46% to 0.06%) for exenatide versus insulin (P = 0.185), and -0.37% (95% CI -0.63% to -0.12%) for exenatide versus pioglitazone (P = 0.002).
    1 context sentence
    Summary · context
    In this 48-week, multicentre, parallel-group study, 416 patients newly diagnosed with type 2 diabetes were randomly assigned 1 : 1 : 1 to receive exenatide, insulin or pioglitazone.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In newly diagnosed type 2 diabetes, exenatide showed the greatest improvements in DI, weight, blood pressure and lipid profile among the three treatments (exenatide, insulin, pioglitazone).

    In plain wordsIn newly diagnosed diabetes, exenatide showed the greatest improvements in DI, weight, blood pressure and lipid profile among exenatide, insulin and pioglitazone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Direction not reportedGreatest improvement in DI, weight, blood pressure and lipid profile among the three treatments
    Study

    n: not reported in source

    Comparator
    insulin and pioglitazone
    Analysis
    Secondary
    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    Dose not stated · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    Significant improvements from baseline in AIR, PI/I and DI were observed with all treatments, with the greatest improvements in DI, as well as weight, blood pressure and lipid profile, observed with exenatide.
    1 context sentence
    Summary · context
    In this 48-week, multicentre, parallel-group study, 416 patients newly diagnosed with type 2 diabetes were randomly assigned 1 : 1 : 1 to receive exenatide, insulin or pioglitazone.

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 05HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialMechanism

    In newly diagnosed type 2 diabetes, AIR, PI/I and DI improved from baseline with all treatments, including exenatide.

    In plain wordsIn patients with newly diagnosed diabetes, beta-cell measures AIR, PI/I and DI improved from baseline with all treatments, including exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Direction not reportedBeta-cell function changes across treatments
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Significant improvements from baseline in AIR, PI/I and DI were observed with all treatments, with the greatest improvements in DI, as well as weight, blood pressure and lipid profile, observed with exenatide.
    1 context sentence
    Summary · context
    In this 48-week, multicentre, parallel-group study, 416 patients newly diagnosed with type 2 diabetes were randomly assigned 1 : 1 : 1 to receive exenatide, insulin or pioglitazone.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02303730

Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes

Fudan Universityn = 76Mar 2015 to Nov 2017

Diabetes Mellitus, Type 2 · Non-alcoholic Fatty Liver Disease

Trial pageClinicalTrials.govUpdated 28 Aug 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.